On July 10, 2025, Moderna’s Spikevax COVID-19 vaccine received full U.S. FDA approval for children aged 6 months through 11 years who are at increased risk for severe COVID-19 disease. This marks a transition from its previous Emergency Use Authorization (EUA) status for this age group. The approval was based on the FDA’s scientific review, despite concerns about the lack of pediatric safety data and potential adverse events like myocarditis and pericarditis.
Moderna CEO Stéphane Bancel highlighted the ongoing threat of COVID-19 to children with underlying conditions. However, critics have raised questions about the decision-making process within the FDA and potential insider trading, as Moderna’s stock value surged days before the announcement.
The FDA has updated package inserts to include stronger warnings about possible side effects. Despite these updates, questions remain about why similar approval was not granted to Pfizer’s product and whether there were broader strategic considerations within the Department of Health and Human Services (HHS).
The recent approval places pressure on the CDC Advisory Committee on Immunization Practices (ACIP) to provide guidance on how this vaccine should be used. Historically, ACIP recommendations influence CDC policy but require acceptance by the CDC Director.
Robert W Malone MD, MS expressed skepticism about the transparency of data supporting this decision and emphasized that legal liability concerns heavily influence medical practice in the U.S. He also noted that vaccine manufacturers have lobbied successfully for liability shields.
Questions persist regarding which pre-existing conditions qualify children for vaccination under this new approval and what data supports the benefits outweighing risks for these groups. As ACIP prepares to address these issues in upcoming meetings, stakeholders await further clarity on how this decision will impact public health guidelines.
Information from this article can be found here.
